Gainers
- Reshape Lifesciences RSLS stock increased by 22.3% to $0.47 during Thursday's pre-market session. The market value of their outstanding shares is at $6.1 million.
- Esperion Therapeutics ESPR shares rose 21.85% to $1.84. The company's market cap stands at $209.2 million.
- Femasys FEMY stock increased by 20.98% to $0.92. The company's market cap stands at $19.8 million.
- Bio-Path Hldgs BPTH stock moved upwards by 20.34% to $0.59. The market value of their outstanding shares is at $7.2 million.
- Codexis CDXS stock moved upwards by 19.61% to $2.5. The company's market cap stands at $174.5 million.
- Akso Health Group AHG stock rose 19.28% to $0.68. The market value of their outstanding shares is at $15.5 million.
Losers
- NextCure NXTC shares fell 19.3% to $1.17 during Thursday's pre-market session. The market value of their outstanding shares is at $32.6 million.
- Apellis Pharmaceuticals APLS shares declined by 14.13% to $54.0. The company's market cap stands at $6.3 billion.
- Ocular Therapeutix OCUL stock fell 13.96% to $3.39. The market value of their outstanding shares is at $269.2 million.
- Pasithea Therapeutics KTTA shares decreased by 13.7% to $0.39. The market value of their outstanding shares is at $8.2 million.
- Monte Rosa Therapeutics GLUE stock declined by 10.43% to $4.47. The company's market cap stands at $223.8 million.
- Assure Hldgs IONM shares declined by 10.0% to $0.37. The market value of their outstanding shares is at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
APLSApellis Pharmaceuticals Inc
$33.210.21%
BPTHBio-Path Holdings Inc
$1.18-20.8%
CDXSCodexis Inc
$5.283.12%
ESPREsperion Therapeutics Inc
$2.180.23%
FEMYFemasys Inc
$1.08-1.74%
GLUEMonte Rosa Therapeutics Inc
$6.672.46%
IONMAssure Holdings Corp
$1.86-23.5%
KTTAPasithea Therapeutics Corp
$2.9912.0%
NXTCNextCure Inc
$0.97002.11%
OCULOcular Therapeutix Inc
$8.632.13%
RSLSReshape Lifesciences Inc
$4.38-2.01%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in